Vestor Capital LLC Invests $153,000 in Tempus AI, Inc. (NASDAQ:TEM)

Vestor Capital LLC bought a new stake in Tempus AI, Inc. (NASDAQ:TEM) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,700 shares of the company’s stock, valued at approximately $153,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. NEA Management Company LLC acquired a new position in shares of Tempus AI in the 2nd quarter valued at about $160,048,000. Novo Holdings A S acquired a new position in Tempus AI in the second quarter valued at approximately $142,605,000. Revolution Growth Management Company Inc. purchased a new stake in Tempus AI in the 2nd quarter worth approximately $128,133,000. Alphabet Inc. acquired a new stake in shares of Tempus AI during the 2nd quarter worth approximately $54,289,000. Finally, Lingotto Investment Management LLP purchased a new position in shares of Tempus AI during the 2nd quarter valued at approximately $32,685,000.

Tempus AI Trading Down 0.0 %

NASDAQ TEM opened at $46.05 on Monday. The business’s fifty day moving average is $50.70. The company has a debt-to-equity ratio of 4.50, a quick ratio of 3.52 and a current ratio of 3.70. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $77.00.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, August 6th. The company reported ($6.77) EPS for the quarter, missing analysts’ consensus estimates of ($4.41) by ($2.36). The business had revenue of $165.97 million for the quarter, compared to the consensus estimate of $159.10 million. As a group, sell-side analysts forecast that Tempus AI, Inc. will post -6.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TEM. Needham & Company LLC reiterated a “buy” rating and issued a $47.00 price objective on shares of Tempus AI in a research report on Wednesday, August 7th. William Blair assumed coverage on Tempus AI in a research note on Tuesday, July 9th. They set an “outperform” rating for the company. Longbow Research started coverage on shares of Tempus AI in a research note on Tuesday, July 9th. They issued a “buy” rating and a $48.00 price target on the stock. Bank of America lowered shares of Tempus AI from a “buy” rating to a “neutral” rating and lifted their target price for the company from $45.00 to $60.00 in a research report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. lifted their price objective on Tempus AI from $42.00 to $47.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $48.67.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.